PRMT5 and cancer: Moreover, with ongoing clinical trials of a PRMT5 inhibitor (NCT03614728), our results suggest that assessing ZMYND11 expression levels could enhance the therapeutic potential of PRMT5 inhibition in cancer patients with lower ZMYND11 expression.